BRPI0920552A2 - nanosistemas poliméricos auto-organizáveis multifuncionais - Google Patents

nanosistemas poliméricos auto-organizáveis multifuncionais

Info

Publication number
BRPI0920552A2
BRPI0920552A2 BRPI0920552A BRPI0920552A BRPI0920552A2 BR PI0920552 A2 BRPI0920552 A2 BR PI0920552A2 BR PI0920552 A BRPI0920552 A BR PI0920552A BR PI0920552 A BRPI0920552 A BR PI0920552A BR PI0920552 A2 BRPI0920552 A2 BR PI0920552A2
Authority
BR
Brazil
Prior art keywords
organizing
multifunctional self
nanosystems
polymeric
polymeric nanosystems
Prior art date
Application number
BRPI0920552A
Other languages
English (en)
Inventor
K Iyer Arun
M Amiji Mansoor
Original Assignee
Univ Northeastern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northeastern filed Critical Univ Northeastern
Publication of BRPI0920552A2 publication Critical patent/BRPI0920552A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
BRPI0920552A 2008-10-09 2009-10-09 nanosistemas poliméricos auto-organizáveis multifuncionais BRPI0920552A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10405608P 2008-10-09 2008-10-09
US24635509P 2009-09-28 2009-09-28
PCT/US2009/060175 WO2010042823A1 (en) 2008-10-09 2009-10-09 Multifunctional self-assembling polymeric nanosystems

Publications (1)

Publication Number Publication Date
BRPI0920552A2 true BRPI0920552A2 (pt) 2019-09-24

Family

ID=42100975

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920552A BRPI0920552A2 (pt) 2008-10-09 2009-10-09 nanosistemas poliméricos auto-organizáveis multifuncionais

Country Status (7)

Country Link
US (1) US9173840B2 (pt)
EP (1) EP2352490A4 (pt)
JP (1) JP2012505243A (pt)
AU (1) AU2009302217A1 (pt)
BR (1) BRPI0920552A2 (pt)
CA (1) CA2740125A1 (pt)
WO (1) WO2010042823A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8333962B2 (en) * 2009-08-27 2012-12-18 National Health Research Institutes Controlled release multidrug formulations for spinal cord injury
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
US9918656B2 (en) * 2010-06-25 2018-03-20 Massachusetts Institute Of Technology Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker
WO2012017307A1 (en) * 2010-08-05 2012-02-09 Council Of Scientific & Industrial Research A process for the removal of polymer thermosets from a substrate
EP2645991B1 (en) 2010-12-02 2020-02-12 GreenMark Biomedical Inc. Aptamer bioconjugate drug delivery device
WO2012142410A2 (en) * 2011-04-15 2012-10-18 The Regents Of The University Of California Redox responsive polymeric nanocapsules for protein delivery
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013067537A1 (en) * 2011-11-04 2013-05-10 Univertiy Of Notre Dame Du Lac Nanoparticle-based drug delivery
KR101722948B1 (ko) * 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법
PL2796150T3 (pl) * 2011-12-15 2021-08-30 Bioneer Corporation Nowe koniugaty oligonukleotydowe i ich zastosowanie
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US20130261444A1 (en) * 2012-03-28 2013-10-03 The Uab Research Foundation Photothermal nanostructures in tumor therapy
CA2870967C (en) 2012-04-19 2021-07-13 Purdue Research Foundation Highly branched alpha-d-glucans
EP2841056A4 (en) * 2012-04-23 2015-09-16 Massachusetts Inst Technology STABLE LAYER COATED PARTICLES
WO2014008283A2 (en) * 2012-07-02 2014-01-09 Northeastern University Biodegradable polymeric buffers
US20170136123A1 (en) * 2013-01-10 2017-05-18 Amrita Vishwa Vidyapeetham Stannous doped micro and nano particles for augmented radiofrequency ablation
EP2950785A4 (en) 2013-02-04 2016-09-21 Univ Notre Dame Du Lac NANOPARTICLE-drug delivery systems
CA2917299C (en) 2013-07-05 2020-07-21 Bioneer Corporation Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
US9695421B2 (en) 2013-07-05 2017-07-04 Bioneer Corporation Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016134002A1 (en) * 2015-02-18 2016-08-25 Memorial Sloan Kettering Cancer Center Compositions and methods for nanoparticle-based drug delivery and imaging
AU2016270823B2 (en) 2015-06-01 2020-09-03 California Institute Of Technology Compositions and methods for screening T cells with antigens for specific populations
CN105878212B (zh) * 2016-05-27 2018-06-15 四川大学 一种双重细胞微环境敏感的抗肿瘤载药纳米胶囊及制备方法
CN106727423A (zh) * 2016-10-13 2017-05-31 中国药科大学 一种具有双靶向性的氧化还原敏感性的核交联普鲁兰多糖纳米粒及制备方法
EP3592862A1 (en) 2017-03-08 2020-01-15 California Institute of Technology Pairing antigen specificity of a t cell with t cell receptor sequences
EP3595629A4 (en) * 2017-03-16 2021-01-06 Children's Medical Center Corporation NONVIRAL, NONCATIONIC NANOPARTICLE AND USES THEREOF
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
CN111918675A (zh) 2018-03-28 2020-11-10 格林马克生物医药股份有限公司 磷酸盐交联淀粉纳米颗粒和牙科治疗
CN108562564B (zh) * 2018-03-29 2021-04-02 青岛大学 一种用于菊糖酶活度检测的碳量子点及制备方法和应用
CN109021587B (zh) * 2018-06-07 2020-12-04 宁夏金博乐食品科技有限公司 可食用的明胶基膜及其制备方法
WO2020163630A1 (en) 2019-02-06 2020-08-13 Singular Genomics Systems, Inc. Compositions and methods for nucleic acid sequencing
EP3975841A1 (en) 2019-05-30 2022-04-06 Massachusetts Institute of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
US12680133B2 (en) 2022-04-22 2026-07-14 Singular Genomics Systems, Inc. Methods, compositions, and solid supports for multi-dimensional sequencing
KR102955891B1 (ko) * 2023-03-14 2026-04-23 가톨릭대학교 산학협력단 덱사메타손 및 폴리에스터의 고분자 접합체를 포함하는 자기조립 나노입자, 이의 제조방법 및 이를 포함하는 약물전달용 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
JPS6319561A (ja) 1986-07-11 1988-01-27 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺癌単クロ−ン性抗体
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP0394277B1 (en) 1987-07-15 1998-01-14 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
US5543508A (en) 1987-12-15 1996-08-06 Gene Shears Pty. Limited Ribozymes
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH0734015B2 (ja) 1988-04-25 1995-04-12 和光純薬工業株式会社 微量成分の新規測定法
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6083696A (en) 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
AU6102494A (en) 1993-02-05 1994-08-29 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
AU2018999A (en) 1997-12-31 1999-07-19 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
US6458559B1 (en) 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
PT1198490E (pt) 1999-07-14 2006-06-30 Alza Corp Lipopolimeros neutros e composicoes liposomais que contem os mesmos
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006044660A2 (en) * 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
CA2600085A1 (en) 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
KR101288729B1 (ko) * 2005-04-01 2013-07-23 인터자인 테크놀로지스, 인코포레이티드 약물 전달용 중합체성 마이셀
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8367113B2 (en) * 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties

Also Published As

Publication number Publication date
US20110244048A1 (en) 2011-10-06
WO2010042823A1 (en) 2010-04-15
EP2352490A4 (en) 2013-11-20
EP2352490A1 (en) 2011-08-10
JP2012505243A (ja) 2012-03-01
CA2740125A1 (en) 2010-04-15
US9173840B2 (en) 2015-11-03
AU2009302217A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
FI20085999A0 (fi) Kattoelementti
NO2021006I1 (no) Quofenix, delafloksacin
CR10926A (es) Nuevas 2-aminooxazolinas como ligandos taar1
DK2514818T3 (da) Glucoamylasevarianter
EP2272042A4 (en) SMART CAR COMPLETION
PL2331687T3 (pl) Środki przeciwdrobnoustrojowe
EP2396152A4 (en) Router
EP2345301A4 (en) SOFTWARE-DEFINED RADIO
EP2300641A4 (en) ALKALI ELECTROLYSIS UNIT
BRPI0918087A2 (pt) construção de edifício
DE112009001577A5 (de) Verstellpumpe
BRPI0919559A2 (pt) baterias
BRPI0905074A2 (pt) Desidratador
FI20086252A0 (fi) Radiovastaanotin
DE102009055010A8 (de) Dachanordnung
FR2951218B1 (fr) Pylone de communication
FI20085902A0 (fi) Porrasrakenne
ES1070015Y (es) Rastrillo multifuncional
ATE521549T1 (de) Verschlusskappe
UA20145S (uk) Ринва
ES1068560Y (es) Parapeto mejorado
ES1065566Y (es) Vallado multifuncional
ITPN20080016U1 (it) Chiosco mobile
ES1071223Y (es) Farola
ES1067637Y (es) Separador balistico

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.